Dermata Therapeutics said the first participant has enrolled in a clinical trial of Tome Clearing Treatment, its once-weekly acne product. The company expects to launch it in the first half of 2027, positioning it as a potential second commercial product.
- Trial milestone: The study is evaluating Tome Clearing Treatment in people with acne. The announcement provides no details on the trial’s size, duration or endpoints.
- Launch timing: Dermata’s stated target is to bring the product to market in the first half of 2027. The timing and success of a launch remain uncertain.
- Date discrepancy: The announcement text dates the press release October 29, 2027, but gives a first-half 2027 launch target. That conflicts with the report’s October 29, 2026 date and leaves the announcement’s stated timing unclear.